Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Reata Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RETA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Reata Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
August 31, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
August 16, 2022
On Tuesday, 37 stocks hit new 52-week lows.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
August 12, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
FDA Pushes Decision Date For Reata's Genetic Neuromuscular Disease Candidate
↗
August 09, 2022
Via
Benzinga
Recap: Reata Pharmaceuticals Q2 Earnings
↗
August 08, 2022
Reata Pharmaceuticals (NASDAQ:RETA) reported its Q2 earnings results on Monday, August 8, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
↗
August 09, 2022
Via
Benzinga
Baird Maintains Neutral Rating for Reata Pharmaceuticals: Here's What You Need To Know
↗
August 09, 2022
Baird has decided to maintain its Neutral rating of Reata Pharmaceuticals (NASDAQ:RETA) and lower its price target from $37.00 to $27.00. Shares of Reata Pharmaceuticals are trading down 8.1% over...
Via
Benzinga
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
August 09, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Nasdaq Turns Lower; Crude Oil Rises Over 1%
↗
August 08, 2022
U.S. stocks pared gains toward the end of trading, with the S&P 500 and the Nasdaq turning lower on Monday.
Via
Benzinga
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
↗
August 09, 2022
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
August 08, 2022
Via
Benzinga
Dow, Nasdaq Enjoy Triple-Digit Gains Midday
↗
August 08, 2022
Stocks are extending this morning's gains.
Via
Talk Markets
Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session
↗
August 08, 2022
Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6...
Via
Benzinga
Dow Jumps Over 150 Points; Karuna Therapeutics Shares Spike Higher
↗
August 08, 2022
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday.
Via
Benzinga
Why Reata Pharma Shares Are Trading Lower After Q2 Earnings Update?
↗
August 08, 2022
Reata Pharmaceuticals Inc (NASDAQ: RETA) completed a mid-cycle communication meeting with the FDA regarding the marketing application review status for omaveloxolone for Friedreich's ataxia.
Via
Benzinga
Why U.S. Stocks Are Trading Higher; Tyson Foods Earnings Miss Views
↗
August 08, 2022
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
August 08, 2022
Via
Benzinga
Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
August 08, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For August 8, 2022
↗
August 08, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.
Via
Benzinga
Reata Pharmaceuticals Earnings Preview
↗
August 05, 2022
Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that Reata...
Via
Benzinga
Reata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022
August 01, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors
July 11, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
July 07, 2022
Gainers
Via
Benzinga
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
↗
July 06, 2022
Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.
Via
Benzinga
Reata Pharmaceuticals Earnings Perspective: Return On Capital Employed
↗
June 09, 2022
According to data from Benzinga Pro, during Q1, Reata Pharmaceuticals's (NASDAQ:RETA) reported sales totaled $914.00 thousand. Despite a 13.52% increase in earnings, the company posted a loss of $73.84...
Via
Benzinga
Where Reata Pharmaceuticals Stands With Analysts
↗
May 27, 2022
Over the past 3 months, 4 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:RETA) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Pharma Stock Shoots Up As FDA Accepts NDA For Neuromuscular Disorder Drug Under Priority Review
↗
May 26, 2022
Reata Pharmaceuticals (NASDAQ: RETA) announced that the U.S. Food and Drug Administration has accepted New Drug Application (NDA) for its lead drug candidate omaveloxolone for the treatment of patients...
Via
Benzinga
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
↗
May 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
May 26, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
NASDAQ:RETA Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Reata Pharmaceuticals, Inc.
↗
May 10, 2022
San Diego, CA -- (SBWIRE) -- 05/10/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Reata Pharmaceuticals, Inc.
Via
SBWire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
